NCT04442022Phase 2, phase 3Active not recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants501Estimated

Source updated2026-07-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-06 · 2 fields changed

Primary completion date changed

− Before

~~Dec 2025~~

+ After

Dec 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Treatments or interventions studied

Selinexor (combination therapy)Drug
Selinexor (combination therapy)Drug
Selinexor (combination therapy)Drug
Placebo matching for Selinexor (combination therapy)Drug
Rituximab (combination therapy)Drug
Rituximab (combination therapy)Drug
Gemcitabine (combination therapy)Drug
Dexamethasone (combination therapy)Drug
Cisplatin (combination therapy)Drug
Selinexor (continuous therapy)Drug
Placebo matching for Selinexor (continuous therapy)Drug

Primary outcomes · main study measures

Read the study measures

measure: Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014; timeFrame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization); measure: Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014; timeFrame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history